Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

39.30
+0.33000.85%
Post-market: 39.300.00000.00%16:07 EDT
Volume:1.04M
Turnover:41.32M
Market Cap:3.69B
PE:-6.25
High:40.13
Open:39.20
Low:39.18
Close:38.97
Loading ...

Ultragenyx Pharmaceutical: Strong Revenue Forecasts and Pipeline Advancements Justify Buy Rating

TIPRANKS
·
13 Jan

BRIEF-Ultragenyx Pharmaceutical Inc Says 2025 Revenue Guidance $640 Mln-$670 Mln

Reuters
·
13 Jan

Ultragenyx Pharmaceutical Inc - 2025 Revenue Guidance $640M-$670M

THOMSON REUTERS
·
13 Jan

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

GlobeNewswire
·
13 Jan

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Zacks
·
07 Jan

Bank of America Securities Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
07 Jan

BRIEF-Ultragenyx Pharma Says EC Expands Evkeeza Approval For HoFH To Children As Young As 6 Months

Reuters
·
06 Jan

Ultragenyx Pharmaceutical: European Commission Extends Approval of Evkeeza to Children as Young as 6-Months Old With Hofh

THOMSON REUTERS
·
06 Jan

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

GlobeNewswire
·
06 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan

Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Dec 2024

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)

TIPRANKS
·
24 Dec 2024

BRIEF-Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
21 Dec 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Dec 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Dec 2024

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
21 Dec 2024

Ultragenyx Pharma Is Maintained at Overweight by Wells Fargo

Dow Jones
·
20 Dec 2024

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswire
·
20 Dec 2024

Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial

MT Newswires Live
·
20 Dec 2024

BRIEF-Ultragenyx Announces First Patient Dosed In Pivotal Phase 3 Aspire Study Evaluating Gtx-102 In Angelman Syndrome

Reuters
·
20 Dec 2024